Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms.

Fridlender ZG, Sun J, Singhal S, Kapoor V, Cheng G, Suzuki E, Albelda SM.

Mol Ther. 2010 Nov;18(11):1947-59. doi: 10.1038/mt.2010.159. Epub 2010 Aug 3.

2.
3.

Randomized phase II clinical trial of chemo-immunotherapy in advanced nonsmall cell lung cancer.

Lasalvia-Prisco E, Garcia-Giralt E, Vázquez J, Aghazarian M, Lasalvia-Galante E, Larrañaga J, Spera G.

Biologics. 2008 Sep;2(3):555-61.

4.

Effects of the conventional antitumor therapies surgery, chemotherapy, radiotherapy and immunotherapy on regulatory T lymphocytes in cancer patients.

Lissoni P, Brivio F, Fumagalli L, Messina G, Meregalli S, Porro G, Rovelli F, Vigorè L, Tisi E, D'Amico G.

Anticancer Res. 2009 May;29(5):1847-52.

5.

The immune tolerance of cancer is mediated by IDO that is inhibited by COX-2 inhibitors through regulatory T cells.

Lee SY, Choi HK, Lee KJ, Jung JY, Hur GY, Jung KH, Kim JH, Shin C, Shim JJ, In KH, Kang KH, Yoo SH.

J Immunother. 2009 Jan;32(1):22-8. doi: 10.1097/CJI.0b013e31818ac2f7.

PMID:
19307990
6.

The anticancer immune response: indispensable for therapeutic success?

Zitvogel L, Apetoh L, Ghiringhelli F, André F, Tesniere A, Kroemer G.

J Clin Invest. 2008 Jun;118(6):1991-2001. doi: 10.1172/JCI35180. Review.

7.

Chemotherapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide-specific CTLs.

Correale P, Del Vecchio MT, La Placa M, Montagnani F, Di Genova G, Savellini GG, Terrosi C, Mannucci S, Giorgi G, Francini G, Cusi MG.

J Immunother. 2008 Feb-Mar;31(2):132-47. doi: 10.1097/CJI.0b013e31815b69c8.

PMID:
18481383
8.

Anti-angiogenesis: making the tumor vulnerable to the immune system.

Griffioen AW.

Cancer Immunol Immunother. 2008 Oct;57(10):1553-8. doi: 10.1007/s00262-008-0524-3. Epub 2008 Apr 26. Review.

9.

Numerical and functional defects of blood dendritic cells in early- and late-stage breast cancer.

Pinzon-Charry A, Ho CS, Maxwell T, McGuckin MA, Schmidt C, Furnival C, Pyke CM, López JA.

Br J Cancer. 2007 Nov 5;97(9):1251-9. Epub 2007 Oct 9.

10.

A phase I pilot study of autologous heat shock protein vaccine HSPPC-96 in patients with resected pancreatic adenocarcinoma.

Maki RG, Livingston PO, Lewis JJ, Janetzki S, Klimstra D, Desantis D, Srivastava PK, Brennan MF.

Dig Dis Sci. 2007 Aug;52(8):1964-72. Epub 2007 Apr 10.

PMID:
17420942
11.

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients.

Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, Solary E, Le Cesne A, Zitvogel L, Chauffert B.

Cancer Immunol Immunother. 2007 May;56(5):641-8. Epub 2006 Sep 8.

PMID:
16960692
12.

Two-dimensional electrophoretic proteome study of serum thermostable fraction from patients with various tumor conditions.

Goufman EI, Moshkovskii SA, Tikhonova OV, Lokhov PG, Zgoda VG, Serebryakova MV, Toropygin IY, Vlasova MA, Safarova MR, Makarov OV, Archakov AI.

Biochemistry (Mosc). 2006 Apr;71(4):354-60.

PMID:
16615854
13.

G-CSF increases the number of peripheral blood dendritic cells CD16+ and modifies the expression of the costimulatory molecule CD86+.

Talarn C, Urbano-Ispizua A, Martino R, Batlle M, Fernández-Avilés F, Herrera C, Pérez-Simón JA, Gaya A, Aymerich M, Pétriz J, Marín P, Sierra J, Montserrat E.

Bone Marrow Transplant. 2006 May;37(9):873-9.

PMID:
16547488
14.
15.

Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications.

Ciocca DR, Calderwood SK.

Cell Stress Chaperones. 2005 Summer;10(2):86-103. Review.

16.
17.

Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer.

Mazzaferro V, Coppa J, Carrabba MG, Rivoltini L, Schiavo M, Regalia E, Mariani L, Camerini T, Marchianò A, Andreola S, Camerini R, Corsi M, Lewis JJ, Srivastava PK, Parmiani G.

Clin Cancer Res. 2003 Aug 15;9(9):3235-45.

18.

CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment.

Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P.

Semin Radiat Oncol. 2003 Jul;13(3):176-81. Review.

PMID:
12903007
19.

A new twist on autologous cancer vaccines.

Emens LA.

Cancer Biol Ther. 2003 Mar-Apr;2(2):161-3. No abstract available.

PMID:
12750555
20.

Antitumoral effect of a vaccination procedure with an autologous hemoderivative.

Lasalvia-Prisco E, Cucchi S, Vázquez J, Lasalvia-Galante E, Golomar W, Gordon W.

Cancer Biol Ther. 2003 Mar-Apr;2(2):155-60.

PMID:
12750554

Supplemental Content

Support Center